| Teveten Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Teveten 400 mg | tablet | oral | 1.0 each | OTC |
| Teveten 600 mg | tablet | oral | 1.0 each | OTC |
Biovail Reports Third-Quarter 2007 Financial Results - CNW Telbec (Communiqués de presse)
... 67479 100108 (33) Teveten - - - - (1058) NM ---------------------------------------------------------------------- Total Product Revenues 178321 270015 ...
Fri Nov 09 00:43:47 -0500 2007
Biovail Reports Third-Quarter 2007 Financial Results - CNW Telbec (Communiqués de presse)
... 67479 100108 (33) Teveten - - - - (1058) NM ---------------------------------------------------------------------- Total Product Revenues 178321 270015 ...
Fri Nov 09 00:43:47 -0500 2007
Dishman to buy Solvay fine chemicals unit - DrugResearcher.com
Dishman currently supplies the API for Eprosartan Mesylate (EM) - a hypertensive drug marketed by Solvay under the brand Teveten - and its intermediates, ...
Mon Jul 09 08:12:37 -0400 2007
eprosartan mesylate - The mesylate salt form of eprosartan, a non-biphenyl, non-tetrazole, nonpeptide angiotensin II antagonist with antihypertensive activity. Eprosartan mesylate antagonizes angiotensin II type I receptors in tissues such as vascular smooth muscle and the adrenal gland. This prevents angiotensin II-induced vasoconstriction and prevents angiotensin II-mediated stimulation of aldosterone secretion by the adrenal cortex, which decreases the excretion of sodium and water and increases the excretion of potassium.